Med. praxi. 2015;12(2):77-82

The diagnosis and treatment of multiple sclerosis

doc.MUDr.Martin Vališ, Ph.D., MUDr.Zbyšek Pavelek
Neurologická klinika LF UK a FN Hradec Králové

Multiple sclerosis is an immunopathological disease characterized by an inflammation of the structures of the central nervous system

and neurodegenerative changes in the brain. The initial neurological complaints, due to which the risk of developing clinically definite

multiple sclerosis is suspected, are referred to as clinically isolated syndrome. The diagnosis of the disease is based on the clinical evaluation

of the patient's problems and neurological examination. Magnetic resonance imaging of the brain and spinal cord supported by

cerebrospinal fluid examination plays an indispensable role. The results of clinical studies and research confirm that early diagnosis and

treatment in the initial stages of the disease can significantly slow its progression, preserve the long-term functionality, and prevent permanent

damage to the neural structures. The article presents all the basic options for treatment of various forms and stages of the disease.

Keywords: multiple sclerosis, clinically isolated syndrome, diagnosis, treatment

Published: April 24, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vališ M, Pavelek Z. The diagnosis and treatment of multiple sclerosis. Med. praxi. 2015;12(2):77-82.
Download citation

References

  1. Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS, Remedia, 2014: 2-4.
  2. Krejsek J, Kopecký O, Taláb R. Imunopatogeneze roztroušené sklerózy. Neurologie pro praxi, 2002; 3(5): 236-243.
  3. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunol. 2(9): 762-764. Go to PubMed...
  4. Jedlička P. Epidemiology of multiple sclerosis in Czechoslovakia. Cesk Slov Neurol, N 1986, 49/6 (390-6), 0301-0597.
  5. Vachová M. Epidemie roztroušené sklerózy ve světě. Cesk Slov Neurol N 2012; 75/108(6): 701-706.
  6. Cree B, Vollmer TL. Clinically isolated syndrome evaluation, risk stratification and treatment decision, Adv Stud Med 2008; 8(8): 257-265.
  7. Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, et al. Early treatment of multiple sclerosis: a Latin American experts meeting, Mult Scler. 2009; 15(Suppl 3): S1-S12. Go to original source... Go to PubMed...
  8. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D: Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome, Neurology. 2009; 72(9): 800-805. Go to original source... Go to PubMed...
  9. Schumacher FA, Beeve GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-568. Go to original source... Go to PubMed...
  10. Poser CM, Paty DW, Schelenberg LC, McDonald WI, Davis FA, Eberd GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 1: 227-231. Go to original source... Go to PubMed...
  11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127. Go to original source... Go to PubMed...
  12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria. Ann Neurol 2005; 58: 840-846. Go to original source... Go to PubMed...
  13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
  14. Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, et al. Early treatment of multiple sclerosis: a Latin American experts meeting, Mult Scler. 2009; (15 Suppl 3): S1-S12. Go to original source... Go to PubMed...
  15. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008; 255(Suppl. 1): 37-43. Go to original source... Go to PubMed...
  16. Miller JR. The importace of early diagnosis of multiple sclerosis, J Manag Care Pharm 2004; 10: S4-S11.
  17. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Europ J Neur, 2005; 12: 939-946.
  18. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46(6): 878-886. Go to original source...
  19. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, Lancet. 2007; 370(9585): 389-397. Go to original source... Go to PubMed...
  20. Jacobs L, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med. 2000; 343(13): 898-904. Go to original source... Go to PubMed...
  21. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Fazekas F, Rieckmann P, Bajenaru O, Ravnborg M, Hillert J, Elovaara I, Young C, Wynn D, King J, Lubetzki C, Hartung HP, Myhr KM, Montalban X, Komoly S, Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503-1511. Go to original source... Go to PubMed...
  22. Montalban X, Sastre-Garriga. Diagnosis and trials of clincially isolated syndrome. Lancet neurology 2014; 13(10): 962-963. Go to original source... Go to PubMed...
  23. Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol. 2011; 24(3): 230-237. Go to original source... Go to PubMed...
  24. O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9): 899-910. Go to original source... Go to PubMed...
  25. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2): 91-101. Go to original source... Go to PubMed...
  26. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011; 134(Pt 7): 1914-1924. Go to original source... Go to PubMed...
  27. Turner MJ, LaMorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol. 2013; 261: 29-36. Go to original source... Go to PubMed...
  28. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1829-1839. Go to original source... Go to PubMed...
  29. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30. Go to original source... Go to PubMed...
  30. Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005; 45: 1640. Go to original source... Go to PubMed...
  31. Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55: 1135. Go to original source... Go to PubMed...
  32. Hommes OR, S?rensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 114. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.